Skip to main content

Advertisement

Table 1 Laboratory investigation before and after three years of combined conventional and GH replacement therapy

From: Effect of growth hormone replacement therapy in a boy with Dent's disease: a case report

  24mo pre-GH Baseline 24 mo post-GH 36mo post-GH
  Hydrochlorothiazide Hydrochlorothiazide + phosphate + K-citrate +calcitriol+rhGH Hydrochlorothiazide + phosphate +K-citrate +calcitriol+rhGH Hydrochlorothiazide + phosphate +K-citrate +calcitriol+rhGH
> 2 GH peaks at night (nl > 20 mU/L) 22.0-28.0 nd nd nd
GH peaks with provocative stimuli (nl > 20 mU/L) nd nd nd 33 (2 mo without GH therapy)
IGF-1 (9 y: nl 123-275 ng/ml) (11 y: 139-395 ng/ml) (12 y: 143-693 ng/ml) nd 122 (before GH therapy) 300.5 - 496 (with GH therapy) 90-125 (2 mo without GH therapy)
Calcium (s) (nl 2.1-2.5 mmol/L) 2.4 2.4 2.4 2.3
Phosphate (s) (nl 0.8-1.5 mmol/L) 1.0 0.74 0.96 1-1.25
iPTH (nl 0.95-5.7 pmol/l) n.d 6.1 n.d 2.68
ALP (5-10 yr: 110-341 U/L) (Puberty: < 500) 224.70 926.0 638 160-174
TRP (nl 85-98%) 65-77 75 57 50-60
Creatinine clearance (nl 89-165 ml/min/1.73 m2) 92.8 99.8 107 112.7
β2-microglobulin (nl < 0.03-0.37 mg/24 h) 81.6 nd nd nd
Protein excretion (nl < 0.150 g/24 h) 1.86 3.21 2.1 2.0-3.0
Calcium excretion (nl < 4 mg/kg/24 h) 10.1 10.9 8.9 6.7-7.2
  1. ALP: alkaline phosphatase; iPTH intact parathyroid hormone; nd: not determined; nl: normal level